Review demonstrates therapeutic advances in nanocarrier drug delivery for glioblastoma, highlighting the potential of combined immunotherapy.
The review highlights intersection of cutting-edge nanocarrier-based drug delivery, surface modification of nanocarriers, immunotherapeutic interventions, and combined therapeutic approaches, which are critical for advancing glioblastoma treatment.
No takes yet. Share an insight, caveat, or question.
Dhiman et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: